Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2a Study to Evaluate the Safety, Tolerability, and Early Proof of Concept of TAK-018 for the Prevention of Postoperative Crohn's Disease Recurrence
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 11 Sep 2023
Price :
$35
*
At a glance
- Drugs Sibofimloc (Primary)
- Indications Crohn's disease
- Focus Proof of concept; Therapeutic Use
- Acronyms SYMMETRY
- Sponsors Takeda; Takeda Development Center Americas
- 15 Sep 2022 Status changed from active, no longer recruiting to discontinued due to inability to recruit the expected number of the subjects within the requisite time period.
- 14 Sep 2022 This trial has been completed in France, according to European Clinical Trials Database record.
- 07 Aug 2022 This trial has been discontinued in Germany, according to European Clinical Trials Database record.